Pharmacoeconomic review report. Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation).

Pharmacoeconomic review report. Glecaprevir / pibrentasvir (Maviret) (AbbVie corporation).

Show other versions (38)

Glecaprevir/pibrentasvir (GP) is a fixed-dose combination of two pan-genotypic direct-acting antiviral (DAA) drugs: glecaprevir, a nonstructural viral protein 3/4A (NS3/4A) protease inhibitor; and pibrentasvir, a nonstructural viral protein 5A (NS5A) inhibitor. GP is indicated for the treatment of...

Full description

Saved in:
Bibliographic Details
Online Access: http://www.ncbi.nlm.nih.gov/books/NBK533682/
Full text
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : CADTH, 2018
Series:Common drug review clinical review report.
Subjects:
Protease Inhibitors > economics.
Protease Inhibitors > therapeutic use.
Antiviral Agents > economics.
Antiviral Agents > therapeutic use.
Hepatitis C, Chronic > drug therapy.
Cost-Benefit Analysis.
Canada.
Tables.

Internet

http://www.ncbi.nlm.nih.gov/books/NBK533682/
Full text

Similar Items